ArticleMetabolomics : Official journal of the Metabolomic Society2025
SAM486A-induced inhibition of AMD1: metabolic and epigenetic implications in non-small cell lung cancer cells.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications.Experimental hematology & oncology · 2026Review
- Review
- The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASBiological research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionPolyamines (putrescine, spermidine, and spermine) are essential molecules for DNA stability and tumor cell proliferation, including in non-small cell lung cancer (NSCLC). AMD1 (S-adenosylmethionine decarboxylase), a critical enzyme in polyamine metabolism, decarboxylates S-adenosylmethionine, a central methyl group donor. SAM486A, an AMD1 inhibitor, has demonstrated therapeutic potential in hematologic and solid tumors.
objectivesThis study evaluates the effects of SAM486A on NSCLC cell lines A549 and H1299, focusing on polyamine metabolism, DNA methylation, cell proliferation, migration, and eIF5A hypusination.
methodsUntargeted GC-MS metabolomics, followed by Ingenuity Pathway Analysis (IPA), was conducted to evaluate the broad metabolic impact of SAM486A. Further characterizations were performed using Western blotting, cell viability, ELISA, and migration assays in A549 and H1299 cells treated with SAM486A. Transcriptomic and survival analyses from the TCGA-LUAD cohort were also integrated to assess clinical relevance.
resultsSAM486A reduced proliferation and migration in both NSCLC cell lines, with A549 displaying greater sensitivity. Metabolomic profiling revealed distinct responses: A549 accumulated L-methionine and showed reduced cysteine and spermidine, while H1299 exhibited increased cysteine and preserved spermidine levels. IPA predicted a shift toward DNA methylation in A549, which was experimentally confirmed by increased 5-methyl-2'-deoxycytidine levels. eIF5A hypusination remained unchanged in both lines. Spermidine rescue experiments showed functional recovery in H1299, but not A549, supporting differential polyamine uptake. Transcriptomic and survival analyses in LUAD patients mirrored these findings, linking low AMD1 expression to favorable outcomes.
conclusionsThese findings suggest that AMD1 inhibition by SAM486A induces a metabolic and epigenetic phenotype resembling that of LUAD tumors with favorable prognosis, supporting its potential as a targeted therapeutic strategy in NSCLC subsets with low AMD1 expression.
Indexed as
Identifiers
40515967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.